Optimizing treatment for lymphoma in cats
Abstract
The role of antibacterial agents within lymphoma treatment protocols remains unresolved in both human and vete r inary medicine. The present study aimed to evaluate the clinical efficacy of combining the COP protocol (vincristine, cyclophosphamide, and prednisolone) with azithromycin in cats with lymphoma. The results demonstrated that the addition of azithromycin to the chemotherapy protocol increased median overall survival by 20% and median progre s sion-free survival by 30%. Furthermore, incorporation of azithromycin into the treatment regimen led to a 30% increase in complete response rates, accompanied by a twofold reduction in the risk of disease progression. Importantly, azithr o mycin administration did not increase the incidence of adverse effects; on the contrary, it reduced the proportion of patients exhibiting vomiting, diarrhoea, and lymphopenia by 2.4-fold (from 29.2% to 12.5%). In cats with lymphoma and concurrent FeLV-positive status, the combination of the COP protocol (vincristine, cyclophosphamide, and predn i solone) with azithromycin resulted in a 30% increase in median survival (from 156 to 201 days) and prolonged time to disease progression by 30% (from 102 to 136 days). The combined use of vincristine, cyclophosphamide, prednisolone, and azithromycin was associated with improved clinical outcomes across all disease stages, as evidenced by a 20% increase in median survival. Given the multisystemic nature of feline lymphoma and the systemic effects of azithrom y cin, its use may represent a promising adjunctive therapeutic strategy. Further studies are warranted to investigate its clinical efficacy in greater detail, including its safety profile and the underlying pathogenetic mechanisms of its action on both primary tumours and metastatic lesions.References
Akhunzianov, A. A., Nesterova, A. I., Wanrooij, S., Filina, Y. V., Rizvanov, A. A., & Miftakhova, R. R. (2023). Unravelling the therapeutic potential of antibiotics in hypoxia in a breast cancer MCF-7 cell line model. International Journal of Molecular Sciences, 24(14), 11540.
Almendros, A., Chan, L. K., Dos Santos Horta, R., Nekouei, O., Hill, F., & Giuliano, A. (2024). Description and characterization of different types of lymphoma in cats in Hong Kong. Animals, 14(11), 1654.
Ansari, A. W., Ahmad, F., Raheed, T., Jochebeth, A., Mateo, J. M. P., Abdulrahman, N., Joy, E. F., Alam, M. A., Buddenkotte, J., Hamoudi, R. A., & Steinhoff, M. (2023). Azithromycin downregulates ICOS (CD278) and OX40 (CD134) expression and mTOR activity of TCR-activated T cells to inhibit proliferation. International Immunopharmacology, 124, 110831.
Barrs, V. R., & Beatty, J. A. (2012). Feline alimentary lymphoma: 1. Classification, risk factors, clinical signs and non-invasive diagnostics. Journal of Feline Medicine and Surgery, 14(3), 182–190.
Beatty, J. (2014). Viral causes of feline lymphoma: retroviruses and beyond. Veterinary Journal, 201(2), 174–180.
Bernardo Marques, G., Ponce, F., Beaudu-Lange, C., Béguin, J., Boissy, L., Chavalle, T., Denoeux, P., Diop, N., Ferro, L., Floch, F., Lajoinie, M., Sayag, D., Barrett, L. E., & Chamel, G. (2024). Feline high-grade and large granular lymphocyte alimentary lymphomas treated with COP- or CHOP-based chemotherapy: A multi-centric retrospective study of 57 cases. Veterinary and Comparative Oncology, 22(2), 186–197.
Chuenngam, T., & Chermprapai, S. (2025). First case report of successful treatment of Mycobacterium abscessus infection in a cat in Thailand. Animals, 15(7), 925.
Collette, S. A., Allstadt, S. D., Chon, E. M., Vernau, W., Madewell, B. R., Rodriguez, C. O., & Skorupski, K. A. (2016). Treatment of feline intermediate- to high-grade lymphoma with a modified CHOP protocol: 119 cases (2006–2012). Veterinary and Comparative Oncology, 14(S1), 14–22.
Cristo, T. G., Biezus, G., Noronha, L. F., Pereira, L. H. H. S., Withoeft, J. A., Furlan, L. V., Costa, L. S., Traverso, S. D., & Casagrande, R. A. (2019). Feline lymphoma and a high correlation with feline leukaemia virus infection in Brazil. Journal of Comparative Pathology, 166, 20–28.
Ferreri, A. J., Sassone, M., Kiesewetter, B., Govi, S., Scarfò, L., Donadoni, G., & Raderer, M. (2015). High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): The HD-K phase II trial. Annals of Oncology, 26(8), 1760–1765.
Holenova, K., Odatzoglou, P., & Taylor, F. (2025). A retrospective descriptive study of colorectal large or intermediate cell lymphoma in cats managed with surgical resection and/or medical management. Journal of Feline Medicine and Surgery, 27(6), 1098612X251338641.
Hunter, R. P., Lynch, M. J., Ericson, J. F., Millas, W. J., Fletcher, A. M., Ryan, N. I., & Olson, J. A. (1995). Pharmacokinetics, oral bioavailability and tissue distribution of azithromycin in cats. Journal of Veterinary Pharmacology and Therapeutics, 18(1), 38–46.
Husník, R., Gaschen, F., Fletcher, J., & Gaschen, L. (2020). Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats. Journal of Veterinary Internal Medicine, 34, 1440–1446.
Kadota, J., Mizunoe, S., Kishi, K., Tokimatsu, I., Nagai, H., & Nasu, M. (2005). Antibiotic-induced apoptosis in human activated peripheral lymphocytes. International Journal of Antimicrobial Agents, 25(3), 216–220.
Karamanolis, N. N., Kounatidis, D., Vallianou, N. G., Dimitriou, K., Tsaroucha, E., Tsioulos, G., Anastasiou, I. A., Mavrothalassitis, E., Karampela, I., & Dalamaga, M. (2024). Unraveling the anti-cancer mechanisms of antibiotics: Current insights, controversies, and future perspectives. Antibiotics, 14(1), 9.
Kiselow, M. A., Rassnick, K. M., McDonough, S. P., Goldstein, R. E., Simpson, K. W., Weinkle, T. K., & Erb, H. N. (2008). Outcome of cats with low-grade lymphocytic lymphoma: 41 cases (1995–2005). Journal of the American Veterinary Medical Association, 232(3), 405–410.
Kopecny, L., Palm, C. A., Skorupski, K. A., Delgado, M., & Rebhun, R. B. (2020). Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin. Journal of Veterinary Internal Medicine, 34(5), 2048–2055.
Lagler, H., Kiesewetter, B., Dolak, W., Obermueller, M., Simonitsch-Klupp, I., Lukas, J., Neuper, O., Lamm, W. W., Mayerhoefer, M. E., & Raderer, M. (2019). Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. Hematological Oncology, 37(1), 22–26.
Lamb, R., Ozsvari, B., Lisanti, M. P., & Sotgia, F. (2015). Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types, without harming normal stem cells. Oncotarget, 6(7–8), 4569–4584.
Larsen, M. M. E., Andersson, A. M., & Arendt, M. (2024). Outcome of treatment with a 10-week COP protocol in cats with intermediate or large cell lymphoma: 27 cases (2014–2023). The Journal of Small Animal Practice, 65(11), 807–816.
Louwerens, M., London, C. A., Pedersen, N. C., & Lyons, L. A. (2005). Feline lymphoma in the post-feline leukemia virus era. Journal of Veterinary Internal Medicine, 19(3), 329–335.
Mizunoe, S., Kadota, J., Tokimatsu, I., Kishi, K., Nagai, H., & Nasu, M. (2004). Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. International Immunopharmacology, 4(9), 1201–1207.
Moore, A. (2013). Extranodal lymphoma in the cat: prognostic factors and treatment options. Journal of Feline Medicine and Surgery, 15(5), 379–390.
Nardo, G., Pantziarka, P., & Conti, M. (2024). Synergistic potential of antibiotics with cancer treatments. Cancers, 17(1), 59.
Ohe, M., & Hashino, S. (2016). Successful treatment of angioimmunoblastic T-cell lymphoma with clarithromycin. Blood Research, 51(2), 139–142.
Pirosa, M. C., Sassone, M., Kiesewetter, B., Guillermo, A. L., Devizzi, L., Domènech, E. D., Tucci, A., Mannina, D., Merli, M., Salar, A., Visco, C., Esposito, F., Bonomini, L., Zucca, E., Ferreri, A. J. M., & Raderer, M. (2023). IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma. Haematologica, 108(6), 1671–1675.
Ratzinger, F., Haslacher, H., Poeppl, W., Hoermann, G., Kovarik, J. J., Jutz, S., Steinberger, P., Burgmann, H., Pickl, W. F., & Schmetterer, K. G. (2014). Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Scientific Reports, 4, 7438.
Reiman, R. A., Mauldin, G. E., & Neal Mauldin, G. (2008). A comparison of toxicity of two dosing schemes for doxorubicin in the cat. Journal of Feline Medicine and Surgery, 10(4), 324–331.
Rutherford, S., Gaschen, F., Husnik, R., Fletcher, J., & Gaschen, L. (2022). Ultrasonographic evaluation of the effects of azithromycin on antral motility and gastric emptying in healthy cats. Journal of Veterinary Internal Medicine, 36(2), 508–514.
Sapierzyński, R., Jankowska, U., Jagielski, D., & Kliczkowska-Klarowicz, K. (2015). Large granular lymphoma in six cats. Polish Journal of Veterinary Sciences, 18(1), 163–169.
Sassone, M., Ponzoni, M., & Ferreri, A. J. (2021). Antibiotic treatment for bacteria-associated extranodal marginal zone lymphoma. Annals of Lymphoma, 5, 4.
Scheibenpflug, R., Obermüller, M., Reznicek, G., Neuper, O., Lamm, W. W., Raderer, M., & Lagler, H. (2021). Azithromycin concentrations during long-term regimen, a pilot study in patients with MALT lymphoma. Scientific Reports, 11(1), 18460.
Smallwood, K., Harper, A., & Blackwood, L. (2021). Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma. Journal of Feline Medicine and Surgery, 23(8), 722–729.
Stein, T. J., Pellin, M., Steinberg, H., & Chun, R. (2010). Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids. Journal of the American Animal Hospital Association, 46(6), 413–417.
Taylor, S. S., Goodfellow, M. R., Browne, W. J., Walding, B., Murphy, S., Tzannes, S., Gerou-Ferriani, M., Schwartz, A., & Dobson, J. M. (2009). Feline extranodal lymphoma: Response to chemotherapy and survival in 110 cats. Journal of Small Animal Practice, 50(11), 584–592.
Teske, E., van Straten, G., van Noort, R., & Rutteman, G. R. (2002). Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: New results with an old protocol. Journal of Veterinary Internal Medicine, 16(2), 179–186.
Thamm, D. H. (2019). Novel treatments for lymphoma. The Veterinary Clinics of North America, Small Animal Practice, 49(5), 903–915.
Vail, D. M., Thamm, D. H., & Liptak, J. M. (2019). Hematopoietic tumors. In: Vail, D. M., Thamm, D. H., & Liptak, J. M. Withrow and MacEwen's Small Animal Clinical Oncology. Sixth Edition. Saunders. Pp. 688–772.
Venditto, V. J., Haydar, D., Abdel-Latif, A., Gensel, J. C., Anstead, M. I., Pitts, M. G., Creameans, J., Kopper, T. J., Peng, C., & Feola, D. J. (2021). Immunomodulatory effects of azithromycin revisited: Potential applications to COVID-19. Frontiers in Immunology, 12, 574425.
Versteegh, H., Zandvliet, M. M. J. M., Feenstra, L. R., van der Steen, F. E. M. M., & Teske, E. (2023). Feline lymphoma: Patient characteristics and response outcome of the COP-protocol in cats with malignant lymphoma in the Netherlands. Animals, 13(16), 2667.
Waite, A. H., Jackson, K., Gregor, T. P., & Krick, E. L. (2013). Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998–2008). Journal of the American Veterinary Medical Association, 242(8), 1104–1109.
Zwahlen, C. H., Lucroy, M. D., Kraegel, S. A., Madewell, B. R., & Rodriguez, C. O. (1998). Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993–1997). Journal of the American Veterinary Medical Association, 213(8), 1144–1149.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
